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Summary
Chronic inflammation predisposes tissue to cancer development; however, regulatory mechanisms underlying recruitment
of innate leukocytes toward developing neoplasms are obscure. We report that genetic elimination of mature T and B
lymphocytes in a transgenic mouse model of inflammation-associated de novo epithelial carcinogenesis, e.g., K14-HPV16
mice, limits neoplastic progression to development of epithelial hyperplasias that fail to recruit innate immune cells.
Adoptive transfer of B lymphocytes or serum from HPV16 mice into T and B cell-deficient/HPV16 mice restores innate
immune cell infiltration into premalignant tissue and reinstates necessary parameters for full malignancy, e.g., chronic
inflammation, angiogenic vasculature, hyperproliferative epidermis. These findings support a model in which B lympho-
cytes are required for establishing chronic inflammatory states that promote de novo carcinogenesis.S I G N I F I C A N C E
Despite compelling data indicating a functional link between inflammation and cancer, pathways regulating initiation of chronic
inflammation during tumorigenesis are obscure. We demonstrate that B lymphocytes are critical for initiating chronic inflammation
during premalignancy and thus support the concept that oncogene expression in “initiated” cells alone is not sufficient for full
malignant progression. Instead, additional signals provided by adaptive and innate immune cells are required for elaboration of
the malignant state. Our results suggest that pharmacological interventions targeting B lymphocytes and/or recruitment of innate
immune cells toward premalignant tissue represent viable cancer chemopreventative strategies.Introduction
Reciprocal interactions between genetically altered “initiated”
cells, responding host cells such as fibroblasts, innate immune
cells and vascular cells, and molecules undergoing remodeling
in the surrounding microenvironment regulate efficient tumor
development (Bissell and Radisky, 2001). The significance of
innate immune cell involvement in cancer development has re-
cently been recognized (Balkwill et al., 2005; Coussens and
Werb, 2002). Initial circumstantial evidence linking inflamma-
tion with cancer was provided by clinical data correlating in-
filtration of innate immune cells into malignant tissue with poor
clinical outcome (Coussens and Werb, 2002) and population-
based studies revealing increased cancer incidence in individ-
uals affected by chronic inflammatory disorders such as pan-
creatitis, Crohn’s disease, and ulcerative colitis (Shacter and
Weitzman, 2002; Thun et al., 2004). Causal demonstration of
a functional link between inflammation and cancer has been
provided by clinical studies reporting reduced cancer inci-
dence in patients treated long-term with anti-inflammatory
drugs (Turini and DuBois, 2002). Mechanistic in vivo studies
have implicated proteolytic enzymes released by inflammatory
cells (Coussens et al., 1999), transcription factor NFκB, and
the potent proinflammatory cytokine tumor necrosis factor-α
(Greten et al., 2004; Pikarsky et al., 2004) as functionally impor-CANCER CELL : MAY 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INC.tant proteins potentiating inflammation-associated cancer de-
velopment. Taken together, there is compelling evidence indi-
cating that identification of critical molecules involved in
activating or sustaining chronic inflammation, or downstream
molecules responding to activated innate immune cells, may
provide efficacious cancer chemopreventative targets.
In mammals, organs are equipped with defense programs
that facilitate rapid responses to tissue damage, e.g., activation
of the complement system, mobilization of resident sentinel
cells (dendritic cells, mast cells, macrophages), and increased
levels of soluble proinflammatory mediators (Kupper and Fuhl-
brigge, 2004). Acute mobilization of these pathways arrests tis-
sue damage and removes “damaged” cells to restore tissue
homeostasis. When critical parameters of these programs are
dysregulated, chronic disease states result, e.g., lupus, Alz-
heimer’s and heart disease, arthritis, asthma, pancreatitis, and
inflammatory bowel disease (Firestein, 2003; Kupper and Fuhl-
brigge, 2004). Mechanistic analysis of experimental animal
models representative of some of these chronic disorders has
revealed interactions between innate and adaptive immune
cells as key determinants of disease pathogenesis (Gould et
al., 2003; Ji et al., 2002). Since chronic inflammation is consid-
ered a risk factor for development of certain cancers (Thun et
al., 2004), we hypothesized that similar interactions between
innate and adaptive immune cells may potentiate malignantDOI 10.1016/j.ccr.2005.04.014 411
A R T I C L Eprogression in at-risk “initiated” tissue. To address this, we
took a genetic approach and utilized a transgenic mouse
model of multistage epithelial carcinogenesis where early re-
gion genes of human papillomavirus type 16 (HPV16) are ex-
pressed as transgenes under control of the human keratin 14
(K14) promotor/enhancer, i.e., K14-HPV16 mice (Arbeit et al.,
1994), and intercrossed them with Recombination-Activating
Gene-1 homozygous null (RAG-1−/−) mice deficient for mature
B and T lymphocytes (Mombaerts et al., 1992). The conse-
quence of adaptive immune deficiency in HPV16 mice is failure
to induce leukocyte recruitment and absence of chronic inflam-
mation in premalignant skin. As a result, tissue levels of vas-
cular endothelial growth factor-A (VEGF-A) and gelatinolytic
metalloproteinases remain at steady-state levels, blood vascu-
lature remains quiescent, oncogene-positive keratinocytes fail
to attain a hyperproliferative phenotype, and carcinoma inci-
dence is reduced. We report that transfer of B cells or serum
from HPV16 mice into HPV16/RAG-1−/− mice restores charac-
teristic chronic inflammation in premalignant skin and reinstates
regulatory mechanisms necessary for activation of angiogenic
vasculature and keratinocyte hyperproliferation. Taken to-
gether, these data indicate that B cells play a crucial role in the
onset of chronic inflammation associated with epithelial can-
cer development.
Results
Reduced infiltration of innate immune cells in
premalignant skin of HPV16/RAG-1−/− mice
As is observed in human neoplasms (Takanami et al., 2000;
Toth-Jakatics et al., 2000), premalignant skin in HPV16 mice is
characterized by infiltration of innate immune cells (Coussens
et al., 1999; de Visser et al., 2004). Given the crucial role of the
adaptive immune system during initiation of several inflam-
matory diseases (Gould et al., 2003; Lee et al., 2002), we hy-
pothesized that B and/or T lymphocytes might contribute to
activation of innate immune responses during early neoplastic
progression in HPV16 mice. To assess this, we generated
HPV16/RAG-1−/−, HPV16/CD4−/−, HPV16/CD8−/−, and HPV16/
CD4−/−/CD8−/− mice and examined key characteristics of pre-
malignant progression in the presence or absence of complete
or partial adaptive immunity.
Quantitative detection of CD45+ cells by flow cytometry re-
vealed reduced infiltrates in premalignant skin of HPV16/
RAG-1−/− mice as compared to HPV16, HPV16/CD4−/−,
HPV16/CD8−/−, and HPV16/CD4−/−/CD8−/− mice (Figure 1A). To
investigate the nature of this reduced inflammatory infiltrate,
we profiled two major leukocyte populations characteristic of
HPV16 premalignant skin, i.e., mast cells (MCs) and granulo-
cytes, and found that both were significantly reduced in
HPV16/RAG-1−/− as compared to age-matched HPV16,
HPV16/CD4−/−, HPV16/CD8−/−, and HPV16/CD4−/−/CD8−/−
skin (Figures 1B and 1C). Thus, in the absence of B and T cells,
chronic inflammation characteristic of premalignancy was sig-
nificantly reduced.
Inflammation regulates characteristics of premalignancy
Chronic inflammation potentiates epithelial hyperproliferation,
tissue remodeling, and development of angiogenic vasculature
during premalignancy in HPV16 mice (Coussens et al., 1999;
van Kempen et al., 2002). These effects are, in part, mediated412via release of bioactive mediators, growth factors, and extra-
cellular proteases from leukocytes (Coussens et al., 1999;
Coussens et al., 2000). Since leukocyte infiltration is signifi-
cantly reduced in HPV16/RAG-1−/− skin (Figure 1), we hypothe-
sized that characteristic parameters of premalignancy reg-
ulated by leukocytes (i.e., tissue remodeling, gelatinolytic
activity, VEGF-A levels, development of angiogenic vascula-
ture, and epithelial hyperproliferation) might also be attenuated.
We assessed gelatinolytic activity in lysates from premalig-
nant skin of HPV16 and HPV16/RAG-1−/− mice by enzyme so-
lution assays (Rhee et al., 2004). Gelatinolytic activity in HPV16
skin incrementally increased during premalignancy; however,
no significant changes were observed in HPV16/RAG-1−/− skin
(Figure 2A, left panel). We and others have previously reported
that two gelatinolytic proteases from the matrix metalloprotei-
nase (MMP) family, namely MMP-2 and MMP-9, functionally
contribute to cancer development (Coussens et al., 2000; Gi-
raudo et al., 2004); (Bergers et al., 2000); thus, we utilized gela-
tin substrate zymography to assess the presence of distinct
molecular weight forms of MMP-2 and -9 in HPV16/RAG-1−/−
lysates where we found only their latent forms, as compared
to progressively increased amounts of both pro- and active
forms in HPV16 skin (Figure 2A, right panel).
MMP-9 is an important leukocyte-derived extracellular pro-
tease that functionally contributes to cancer development by
potentiating epithelial hyperproliferation and activation of angi-
ogenesis, in part by its ability to induce tissue remodeling and
regulate bioavailability of extracellular matrix (ECM)-seques-
tered VEGF (Bergers et al., 2000; Bergers and Coussens,
2000). Thus, we reasoned that if leukocyte infiltration and levels
of MMP-9 and other gelatinases were reduced in HPV16/RAG-
1−/− skin, levels of VEGF-A might also be reduced, resulting in
diminished development of angiogenic vasculature. We exam-
ined VEGF-A protein levels in skin lysates of HPV16 mice by
ELISA and found a progressive increase at each neoplastic
stage (Figure 2B, upper left panel) that correlated with increas-
ing percentages of CD31+ cells (Figure 2B, upper right panel)
and development of angiogenic vasculature (Figure 2B, bottom
panels). In contrast, age-matched skin from HPV16/RAG-1−/−
mice failed to accumulate VEGF (Figure 2B) or demonstrate
any characteristics of vascular activation associated with angi-
ogenesis (i.e., increased percentage of CD31+ cells, vasodila-
tion or vascular tortuosity; Figures 2B). Similarly, epithelial pro-
liferation was markedly reduced in HPV16/RAG-1−/− versus
age-matched HPV16 skin (Figure 2C, left panel). Taken to-
gether, these data suggest that failure to efficiently recruit in-
nate immune cells into premalignant skin results in reduced
levels of tissue remodeling enzymes and VEGF, deficient devel-
opment of angiogenic vasculature, and attenuated ability of
keratinocytes to achieve hyperproliferative growth character-
istics.
Decreased incidence of squamous cell carcinomas
in HPV16/RAG-1−/− mice
To assess whether absent characteristics of premalignancy in
HPV16/RAG-1−/− mice correlated with reduced carcinoma inci-
dence, we monitored a cohort of HPV16/RAG-1−/− mice (n =
108) for cancer development as compared to a similar cohort
of HPV16 mice (n = 134). HPV16/RAG-1−/− mice developed
hyperplastic skin lesions with a similar 100% penetrance as
HPV16 controls (Figure 2C). At 4 months of age, whereasCANCER CELL : MAY 2005
A R T I C L EFigure 1. Reduced infiltration of innate immune
cells in premalignant skin of HPV16/RAG-1−/−
mice
A: Percentage of CD45+ cells in skin of negative
littermates (−)LM and premalignant HPV16,
HPV16/RAG-1−/−, HPV16/CD4−/−, HPV16/CD8−/−,
and HPV16/CD4−/−/CD8−/− mice at 6 months of
age analyzed by flow cytometry. Results shown
are mean percentages (n = 3–7 mice). Error bars
represent SEM and asterisks (*) indicate statistic-
ally significant differences between age-
matched HPV16 versus HPV16/RAG-1−/− mice
(p = 0.02, Mann-Whitney).
B: Mast cells (arrowheads, blue staining) during
premalignant progression in skin of (−)LM and
transgenic mice. Values reflect averages from
five high-power fields per mouse and five mice
per category. Error bars represent SEM, asterisk
(*) indicates statistically significant differences
between age-matched HPV16 versus HPV16/
RAG-1−/− mice (p < 0.05, Mann-Whitney). Dashed
line, epidermal-dermal interface; epidermis, e;
dermis, d; cartilage, c. Scale bar, 50 m.
C: Granulocytes during premalignant pro-
gression in skin of (−)LM and transgenic mice.
Quantitative values (left panel) represent num-
ber of granulocytes (middle panel; arrowheads,
brown stained cells), averaged from five high-
power fields per mouse and five mice per cate-
gory. Error bars represent SEM, and asterisk (*)
indicates statistically significant differences be-
tween age-matched HPV16 versus HPV16/
RAG-1−/− or HPV16/CD8−/− mice (p < 0.05 Mann-
Whitney). Histograms representing single-cell
suspensions of premalignant HPV16 and HPV16/
RAG-1−/− skin (4 months of age) analyzed by
flow cytometry. Scale bar, 50 m.100% of HPV16 mice manifest focally dysplastic epidermis,
this was not found in age-matched HPV16/RAG-1−/− mice; in
fact, a mere 12% of HPV16/RAG-1−/− mice ever developed fo-
cally dysplastic epidermis (Figure 2C). Moreover, absence of B
and T cells significantly reduced the overall incidence of inva-
sive carcinomas in HPV16/RAG-1−/− mice, where only 6.4% of
mice developed SCCs as compared to the w47% in control
HPV16 mice (p % 0.0045, Log rank analysis; Figure 2C). This
dramatic reduction in carcinoma incidence in HPV16/RAG-1−/−
mice is in contrast to the modest reduction in HPV16/CD4−/−
mice (41%) and characteristic w50% incidence in HPV16/
CD8−/− mice (Daniel et al., 2003).
Immunoglobulin deposition characterizes HPV16
premalignant skin
Since genetic elimination of CD4+ and/or CD8+ cells did not
alter leukocyte recruitment into premalignant HPV16 as com-
pared to HPV16/RAG-1−/− skin (Figure 1), we hypothesized that
B cells might regulate innate immune cell response; however,CANCER CELL : MAY 2005B cells do not infiltrate premalignant HPV16 skin (Figure 3A).
B cells can however exert distal effects via production of im-
munoglobulins (Ig) that subsequently circulate in blood and
accumulate in tissues where they regulate cellular pathways
via engagement of complement proteins, formation of immune
complexes, or activation of cell surface receptors on resident
leukocytes (Firestein, 2003; Hogarth, 2002). Thus, we assessed
spatial and temporal depositions of IgG, IgG1, IgG2a, IgM, IgA,
and IgE in HPV16 skin (Figure 3B). In nontransgenic skin, IgM
and IgG immunoreactivity was detected in the dermis at low
levels (Figure 3B), whereas IgG1, IgG2a, IgA, and IgE were not
detected (data not shown). In contrast, moderate IgM and
strong IgG immunoreactivity was detected in dermal stroma by
1 month of age in HPV16 skin that became more pronounced
by 6 month (Figure 3B). IgM was localized proximal to epithelial
basement membranes, whereas extensive regions of IgG im-
munoreactivity were also detected throughout the dermis, re-
flecting IgG1 predominantly, and to a lesser extent IgG2a (Fig-
ure 3B). IgA and IgE immunoreactivity were not detected in413
A R T I C L EFigure 2. Inflammation regulates neoplastic progression in HPV16 mice
A: Gelatinolytic activities in tissue extracts from (−)LM, HPV16, and HPV16/RAG-1−/− mice measured by enzyme solution assay. Values represent average
change in relative fluorescence units (RFU)/min/g tissue protein (n = 3–5 per time point). Error bars represent SEM, and asterisk (*) indicates statistically
significant differences between age-matched HPV16 versus HPV16/RAG-1−/− mice (p < 0.05, Mann-Whitney). Tissue lysates from (−)LM, HPV16, and HPV16/
RAG-1−/− mice were assessed for relative differences in levels of pro and/or active molecular weight forms of MMP-2 and -9 by gelatin substrate zymog-
raphy.
B: VEGF-A protein levels in skin extracts from (−)LM, HPV16, and HPV16/RAG-1−/− mice assessed by ELISA. Percentage of CD31+ cells analyzed by flow
cytometry in ears of (−)LM, HPV16, and HPV16/RAG-1−/− mice. Error bars represent SEM, and asterisk (*) indicates statistically significant differences between
age-matched HPV16 versus HPV16/RAG-1−/− mice (p < 0.05, unpaired t test). Immunolocalization of CD31 (arrowheads, brown staining) in age-matched
skin from (−)LM, HPV16, and HPV16/RAG-1−/− mice. Dashed line, epidermal-dermal interface; epidermal, e; dermal, d; cartilage, c. Scale bar, 50 m.414 CANCER CELL : MAY 2005
A R T I C L E(Figure 3B) coinciding with inflammatory cell infiltration, we hy-mice.
Fluorescent angiography of premalignant HPV16 and HPV16/RAG-1−/− skin (6 months of age). Scale bar, 100 m.
C: Keratinocyte proliferation index in ears of (−)LM and premalignant HPV16 and HPV16/RAG-1−/− mice at 1, 4, and 6 months of age. Values represent an
average from five high-power fields per mouse, with 4 to 8 mice per category. Error bars represent SEM, and asterisk (*) indicates statistically significant
differences between age-matched HPV16 versus HPV16/RAG-1−/− mice (p < 0.05, Mann-Whitney).
D: Incidence of epithelial neoplasms in mice developing hyperplastic skin lesions by 1 month of age (Hyp), dysplasia by 6 months of age (Dys), dysplasia
throughout lifetime, and lifetime incidence of SCCs. Values represent percentages of mice with particular neoplastic phenotypes.Figure 3. Immunoglobulin deposition character-
izes HPV16 premalignant skin
A: Percentages of CD45+, CD8+, CD4+, NK1.1+,
γδTCR+, or B220+/CD19+ cells assessed by flow
cytometry of (−)LM and HPV16 ear tissue at 1, 4,
and 6 months of age. Results shown are mean
percentages (n = 5–7). Error bars represent SEM.
B: Direct immunofluorescence of IgM, IgG,
IgG1, and IgG2a antibodies (arrowheads,
green staining) and nuclei (blue) in skin of (−)LM
and HPV16 mice at 1 and 6 months of age.
Dashed line, epidermal-dermal interface; epi-
dermis, e; dermis, d. Scale bar, 50 m. Boxed
areas A and B are shown enlarged in lower left
two panels.tissue representing any premalignant stage (data not shown).
Together, these data indicate that whereas B cells are not re-
cruited into premalignant tissue, they are activated peripherally
and initiate Ig deposition into neoplastic tissue paralleling
chronic inflammation and premalignant progression in HPV16CANCER CELL : MAY 2005Adoptive transfer of B lymphocytes into HPV16/RAG-1−/−
mice restores characteristics of premalignant progression
Based on the importance of B cells in regulating recruitment
and activation of leukocytes during inflammation-associated
pathologies and the abundant deposition of Ig in HPV16 skin415
A R T I C L Epothesized that B cell deficiency in HPV16/RAG-1−/− mice was,
in part, responsible for their attenuated neoplastic develop-
ment. To assess this, we isolated B220+CD19+ B cells from
spleens and lymph nodes of 3- to 6-month-old HPV16 mice.
At this age, HPV16 mice have pronounced Ig deposition in skin
and thus contain primed and/or memory B cells of desired
specificity (Figure 4A). To exclude a potential activating effect
of labeling B cells with antibodies, a negative purification pro-
cedure was applied by removing all non-B lymphocytes. The
enriched population contained w87% B220+CD19+ B cells,
with the remainder composed predominantly of debris, a small
fraction of NK1.1+ cells (<0.4%), γδ TCR+ cells (<2%), and
<0.1% CD4+ and CD8+ T cells (data not shown and Figure 4A).
This enrichment process did not select for subpopulations of
(activated) B220+CD19+ B cells or alter the activation status of
B220+CD19+ B cells as determined by flow cytometry (Figure
4A, right panel). Enriched B cell populations were adoptively
transferred into 1-month-old HPV16/RAG-1−/− mice, and at
specific time points post-transfer, serum was analyzed for Ig
by ELISA (Figure 4B). Sera from B cell recipient-HPV16/Figure 4. Adoptive transfer of B cells into HPV16/
RAG-1−/− mice results in antibody deposition in
premalignant skin
A: Dot plots showing B (CD19+/B220+), CD4+,
and CD8+ T cell percentages in spleens and
lymph nodes from HPV16 mice before and after
B cell purification. Analysis of activation pheno-
types of B220+/CD19+ B cells before and after
enrichment by flow cytometry reveals percent-
ages of CD69+ and CD138+ cells gated on live
CD19+/B220+ B cells. Mean fluorescence inten-
sity (MFI) of CD23, CD44, and MHC-II antibody
signals of live B220+/CD19+ B cells are shown.
B: Ig levels determined by ELISA in serum from
HPV16 (4 months), HPV16/RAG-1−/− (4 months),
and B cell reconstituted/HPV16/RAG-1−/− mice
at indicated time points after adoptive transfer.
C: Percentages of B220+/CD19+ B cells, CD4+ T,
and CD8+ T cells in spleens of HPV16 (5 months),
HPV16/RAG-1−/− (5 months), and B cell reconsti-
tuted HPV16/RAG-1−/− mice 4 months following
adoptive transfer by flow cytometry.
D: Direct immunofluorescent detection of IgG
(red arrowheads, green staining) in neoplastic
skin of age-matched HPV16, HPV16/RAG-1−/−,
and B cell reconstituted/HPV16/RAG-1−/− mice,
4 months after reconstitution (5 months of age).
Dashed line, epidermal-dermal interface; epi-
dermis, e; dermis, d; cartilage, c; nuclei (blue
staining). Scale bar, 50 m.416RAG-1−/− mice exhibited detectable titers of Ig within 17 days,
reached a stable level by 2 months of age, and remained at
that level for at least 4 months (Figure 4B), indicating that
adoptively transferred B cells survived and remained functional
following transfer. Antibody titers in serum of B cell recipient-
HPV16/RAG-1−/− mice were w3-fold lower than in age-
matched HPV16 mice, an expected observation since only 7 ×
106 B cells were transferred. T cell populations were not ob-
served in lymphoid organs of B cell recipient-HPV16/RAG-1−/−
mice (Figure 4C). Importantly, spatial depositions of Ig in skin of
B cell recipient-HPV16/RAG-1−/− mice was similar, albeit less
pronounced, to age-matched HPV16 mice where patches of
IgG were detectable in dermal stroma 1 month following B cell
transfer (data not shown) that became more pronounced with
age (Figure 4D).
We next investigated whether adoptive transfer of B cells
into HPV16/RAG-1−/− mice restored characteristic parameters
of premalignancy and found that B cell recipient/HPV16/
RAG-1−/− mice exhibited characteristic infiltration of CD45+
leukocytes (Figure 5A) and abundant presence of MCs andCANCER CELL : MAY 2005
A R T I C L EFigure 5. Adoptive transfer of B cells into HPV16/
RAG-1−/− mice restores inflammation in prema-
lignant skin
A: Percentages of CD45+ cells in age-matched
skin from HPV16, HPV16/RAG-1−/−, and B cell re-
constituted HPV16/RAG-1−/− mice (4 months af-
ter B cell transfer) analyzed by flow cytometry.
Error bars represent SEM, and asterisk (*) indi-
cates statistically significant differences be-
tween age-matched HPV16/RAG-1−/− versus B
cell recipient HPV16/RAG-1−/− mice (p < 0.05,
unpaired t test).
B: Mast cells (blue staining cells, arrowheads,
upper panels) and granulocytes (brown staining
cells, arrowheads, lower panels) in ear tissue of
age-matched HPV16/RAG-1−/− and B cell re-
constituted/HPV16/RAG-1−/− mice (4 months af-
ter B cell transfer). Dashed line, epidermal-der-
mal interface; epidermis, e; dermis, d; cartilage,
c. Graphical representation of mast cell num-
bers averaged from five high-power fields per
mouse and four mice per category. Percen-
tage of GR-1+ cells analyzed by flow cytometry
of age-matched ear tissue of HPV16, HPV16/
RAG-1−/−, and B cell reconstituted HPV16/
RAG-1−/− ear skin (4 months after B cell transfer).
Error bars represent SEM, and asterisk (*) indi-
cates statistically significant differences be-
tween age-matched HPV16/RAG-1−/− versus B
cell recipient HPV16/RAG-1−/− mice (p < 0.05,
Mann-Whitney).granulocytes in dermal stroma (Figure 5B), suggesting that B
cells play a crucial role in regulating chronic inflammation asso-
ciated with premalignant progression in HPV16 mice. More-
over, neoplastic skin of B cell recipient-HPV16/RAG-1−/− mice
exhibited restored characteristic parameters of premalignancy
downstream of chronic inflammation, e.g., development of an-
giogenic vasculature and keratinocyte hyperproliferation (Fig-
ures 6A and 6B). Taken together, these data indicate that B
cells are critical adaptive immune cells necessary for innate
immune cell infiltration, activation, and responses downstream
of oncogene expression in neoplastic skin.
Transfer of serum from HPV16 mice into HPV16/RAG-1−/−
mice restores premalignant characteristics
Since abundant Ig deposition in dermal stroma is characteristic
of HPV16 premalignancy (Figure 3), we hypothesized that B
cells exert their effect via production of antibodies or other sol-
uble factors in serum. To assess this, we transferred serum
from 3- to 6-month-old HPV16 mice at weekly intervals into
HPV16/RAG-1−/− mice starting at 1 month of age and continu-
ing for 4 months. After 4 months, we found Ig in HPV16/
RAG-1−/− skin whose spatial deposition was similar, albeit less
pronounced, to age-matched HPV16 mice (Figure 7A). Impor-
tantly, transfer of HPV16 serum into HPV16/RAG-1−/− mice re-
stored infiltration of CD45+ cells (Figure 7B) as well as in-
creased infiltration of MCs and granulocytes as compared to
age-matched HPV16/RAG-1−/− mice (Figure 7C), suggesting
that serum factors in HPV16 mice play a role in regulating
chronic inflammation associated with premalignant progres-
sion. Moreover, premalignant skin of serum transferred-HPV16/
RAG-1−/− mice exhibited enhanced development of angiogenic
vasculature and keratinocyte hyperproliferation as comparedCANCER CELL : MAY 2005to age-matched HPV16/RAG-1−/− mice (Figures 7D and 7E),
similar to that observed following B cell transfer (Figure 6). To
determine the specificity of serum rescue, we transferred se-
rum from nontransgenic mice into 1-month-old HPV16/
RAG-1−/− mice and found no change in phenotype as as-
sessed by Ig deposition, leukocyte infiltration, or vascular ar-
chitecture (unpublished data). Taken together, these data indi-
cate that peripheral B cell responses in HPV16 mice mediate
innate immune cell infiltration, activation, and responses down-
stream of oncogene expression in neoplastic skin via prod-
uction of mediators found in serum.
Discussion
It is well established that chronic inflammation contributes to
cancer development (Balkwill et al., 2005; Coussens and Werb,
2002). It is not clear, however, which mechanisms are responsi-
ble for initiation and/or maintenance of chronic inflammation
associated with developing neoplasms. This study revealed a
provocative new insight into the role of adaptive immunity,
specifically B cells, as important regulators of inflammation-
associated cancer development. Using a transgenic mouse
model of multistage epithelial carcinogenesis, e.g., HPV16
mice, we found that genetic deletion of adaptive immune cells
resulted in attenuated recruitment of innate immune cells to-
ward premalignant skin. As a consequence, tissue remodeling,
angiogenesis, and epithelial hyperproliferation were signifi-
cantly reduced, culminating in reduced carcinoma incidence.
Importantly, transfer of B cells or serum from HPV16 mice into
T and B lymphocyte-deficient/HPV16 mice resulted in restored
Ig deposition in premalignant skin, recruitment of leukocytes,
and characteristic parameters of premalignancy. Together,417
A R T I C L EFigure 6. Adoptive transfer of B cells from HPV16 mice into HPV16/RAG-1−/−
mice restores characteristics of premalignant progression
A: Percentage of CD31+ cells analyzed by flow cytometry from single-cell
suspensions of age-matched HPV16, HPV16/RAG-1−/−, and B cell reconsti-
tuted/HPV16/RAG-1−/− ears (4 months after B cell transfer). Error bars repre-
sent SEM, and asterisk (*) indicates statistically significant differences be-
tween age-matched HPV16/RAG-1−/− versus B cell recipient/HPV16/RAG-1−/−
mice (p < 0.05, unpaired t test). Immunolocalization of CD31 (arrowheads,
brown staining) in age-matched ear tissue of HPV16, HPV16/RAG-1−/−, and
B cell recipient/HPV16/RAG-1−/− mice (4 months after adoptive transfer).
Dashed line, epidermal-dermal interface; epidermis, e; dermis, d; carti-
lage, c. Scale bar, 50 m.
B: Keratinocyte proliferation index in ear tissue of HPV16, HPV16/RAG-1−/−,
and B cell reconstituted/HPV16/RAG-1−/− mice (4 months after adoptive
transfer). Values reflect averages from five high-power fields per mouse,
four mice per category. Error bars represent SEM, and asterisk (*) indicates
statistically significant differences between age-matched HPV16/RAG1−/−
versus B cell recipient/HPV16/RAG-1−/− mice (p < 0.05, Mann-Whitney).these data indicate that peripheral B cell activation is an es-
sential step for early epithelial neoplastic development, and B
cell-derived soluble mediators are necessary for establishing
chronic inflammatory states that potentiate malignant pro-
gression.
B lymphocytes mediate chronic inflammation
B lymphocytes do not infiltrate premalignant skin in HPV16
mice, suggesting that they play an immunomodulatory role in
a paracrine manner following interactions with Langerhans or
dendritic cells presenting skin-derived antigens in draining
lymph nodes and/or spleen. Moreover, since transfer of serum418from HPV16 mice reinstates characteristics of neoplastic pro-
gression to HPV16/RAG-1−/− mice similar to that observed fol-
lowing adoptive transfer of B cells (isolated from HPV16 mice),
we propose that B lymphocytes exert their effect distally via
production of soluble mediators that enter the circulation and
home to premalignant tissues.
What types of serum-derived soluble mediators produced
distally by activated B cells could underlie activation and main-
tenance of chronic inflammation in HPV16 mice? Activated B
cells may regulate chronic inflammation and cancer develop-
ment via altering circulating cytokine and/or chemokine pro-
files/levels. Depending on the scenario, it has been reported
that activated B cells produce CXCL1 chemokines (KC and
MIP-2), IL-4, IL-6, and IL-10 (Hu et al., 2004; Lenert et al., 2005;
Sato et al., 2004; Viau and Zouali, 2005). These chemokines
and cytokines have been implicated in modulating innate im-
munity during pathogenic and/or acute states of inflammation
(Balkwill et al., 2005) and may thus also be involved in mediat-
ing recruitment of leukocytes to neoplastic skin.
Another mechanism whereby B cells are known to exert im-
munomodulatory effects is via antibody production (Viau and
Zouali, 2005). There is ample evidence that Ig-mediated path-
ways participate in the pathogenesis of experimental and clin-
ical inflammatory disorders (Lee et al., 2002; Liu et al., 1993;
Sylvestre and Ravetch, 1996). Mechanisms for this partici-
pation involve Ig-antigen complex formation and subsequent
activation of complement cascades resulting in formation and
liberation of anaphylatoxins, e.g., C3a and C5a, potent proin-
flammatory factors that induce recruitment and activation of
leukocytes (Hartmann et al., 1997). Alternatively, antibodies
could activate innate immune cells via direct engagement with
antibody binding multimeric cell surface Fc receptors (FcR)
(Clynes and Ravetch, 1995).
Premalignant HPV16 skin is characterized by abundant Ig
deposition (absent in HPV16/RAG-1−/− mice, but restored fol-
lowing transfer of serum isolated from HPV16 mice but not
nontransgenic mice); thus, once in the neoplastic microenvi-
ronment, antibodies could mediate recruitment of innate im-
mune cells via activation of complement cascades or engage-
ment of FcR expressed on resident immune cells. Depositions
of complement component C3 are present in HPV16/RAG-1−/−
skin (Figure S2 in the Supplemental Data available with this
article online), indicating that the complement system alone is
not sufficient for induction of chronic inflammation during neo-
plastic progression. Taken together with the fact that C3-defi-
cient/HPV16 mice display characteristic antibody deposition,
chronic inflammation, angiogenesis, and keratinocyte hyper-
proliferation (de Visser et al., 2004), we speculated that anti-
bodies produced distally by activated B cells home to neoplas-
tic skin and modulate chronic inflammation by cross-linking
FcR on resident leukocytes, resulting in an initial “trigger” in-
ducing rapid degranulation and release of proinflammatory me-
diators that further enhance the cascade of activation and re-
cruitment of innate immune cells. To distinguish between the
functional significance of antibodies versus other soluble medi-
ators present in serum, we are currently performing transfer
experiments with purified Igs isolated from HPV16 mice.
This report demonstrates that spontaneous activation of B
cells promotes de novo epithelial carcinogenesis by initiating
chronic inflammation. A link between B cells, antibodies, and
cancer development has been postulated previously, based onCANCER CELL : MAY 2005
A R T I C L EFigure 7. Transfer of serum from HPV16 mice into
HPV16/RAG-1−/− mice enhances premalignant
progression
A: Direct immunofluorescent detection of IgG
antibodies (green staining) and nuclei (blue
staining) in neoplastic skin of age-matched
HPV16, HPV16/RAG-1−/−, and HPV16/RAG-1−/−
mice injected with HPV16 serum at weekly in-
tervals for 4 months (5 months of age). Dashed
line, epidermal-dermal; epidermis, e; dermis, d;
cartilage, c. Scale bar, 50 m.
B: Percentage of CD45+ cells determined by
flow cytometry in age-matched HPV16, HPV16/
RAG-1−/−, and serum transferred/HPV/RAG-1−/−
mice (4 months after initiation of serum transfer).
Error bars represent SEM, and asterisk (*) indi-
cates statistically significant differences be-
tween age-matched HPV16/RAG-1−/− versus se-
rum transferred/HPV16/RAG-1−/− mice (p < 0.05,
Mann-Whitney).
C: Mast cells (blue staining, arrowheads, upper
panels) and granulocytes (brown staining,
arrowheads, lower panels) in ear tissue of
age-matched HPV16/RAG-1−/− and serum
transferred/HPV/RAG-1−/− mice (4 months after
initiation of serum transfer). Dashed line, epider-
mal-dermal interface; epidermis, e; dermis, d;
cartilage, c. Scale bar, 50 m. Values reflect av-
erages from five high-power fields per mouse
and 3 to 7 mice per category. Error bars repre-
sent SEM, and asterisk (*) indicates statistically
significant differences between age-matched
HPV16/RAG-1−/− versus serum transferred/
HPV16/RAG-1−/− mice (p < 0.05, Mann-Whitney).
D: Percentage of CD31+ cells analyzed by flow
cytometry in ear tissue from HPV16, HPV16/
RAG-1−/−, and serum transferred/HPV16/
RAG-1−/− mice (4 months after initiation of serum
transfer). Error bars represent SEM, and asterisk
(*) indicates statistically significant differences
between age-matched HPV16/RAG-1−/− versus
serum transferred/HPV16/RAG-1−/− mice (p <
0.05, Mann-Whitney).
E: Keratinocyte proliferation index in ear tissue of
HPV16, HPV16/RAG-1−/−, and serum transferred/
HPV16/RAG-1−/− mice (4 months after initiation
serum transfer). Values reflect averages from
five high-power fields per mouse (n = 3–7). Error
bars represent SEM, and asterisk (*) indicates
statistically significant differences between age-
matched HPV16/RAG1−/− versus serum transfer-
red/HPV16/RAG-1−/− mice (p < 0.05, Mann-
Whitney).observations that low antibody responder mice are more resis-
tant to tumor induction by carcinogens (Ibanez et al., 1999).
In addition, passive transfer or actively produced antibodies
following vaccination enhance in vivo outgrowth of injected tu-
mor cells (Ishibashi et al., 1978; Nyhus et al., 2001). Moreover,
active immunization of mice carrying a mutant ras oncogene
results in activation of humoral immune responses and enhanced
papilloma formation upon chemical promotion (Schreiber et al.,
2000; Siegel et al., 2000). Other studies have reported that anti-
tumor humoral immune responses potentiate in vivo growth
and invasion of injected murine and human tumor cell lines via
recruitment and activation of granulocytes and macrophages
(Barbera-Guillem et al., 1999; Barbera-Guillem et al., 2002).
Whether these observations are unique for tumor transplanta-
tion where premalignant progression is circumvented orCANCER CELL : MAY 2005whether de novo carcinogenesis follows similar scenarios was
not addressed. In combination with these previous observa-
tions, our data support a role for B cells as important contrib-
utors to the earliest steps of neoplastic progression by regulat-
ing chronic inflammation in premalignant tissues.
Activation of B lymphocytes
during premalignant progression
B lymphocytes responsible for initiating chronic inflammation
in HPV16 skin could be specific for several types of antigens,
e.g., pathogen-derived antigens, neo-antigens, or self-anti-
gens. Several types of human malignancies are associated
with chronic inflammation as a consequence of bacterial infec-
tions, i.e., Helicobacter pylori infection results in chronic inflam-
mation and predisposes to gastric carcinoma (Ernst and Gold,419
A R T I C L E2000). Similarly, chronic colon inflammation caused by bacte-
ria, viruses, or irritants predisposes to colon carcinogenesis
(Shacter and Weitzman, 2002). These clinical observations
suggest a correlation between induction of inflammatory reac-
tions following pathogen or irritant exposure and neoplastic
risk; however, a critical role for B cells has thus far not been
reported. To address the significance of bacterial antigens as
activators of B cell responses and chronic inflammation in
HPV16 mice, we generated a colony of germ-free HPV16 mice.
Analysis of this colony indicates that the relative contribution
of bacterial-specific antigens is minimal (K.E.d.V. et al., unpub-
lished data). Alternatively, B cell responses may be directed
toward neo-antigens, e.g., antigens only present in neoplastic
tissue as a consequence of genetic alteration and expression
of mutant protein, or self-antigens derived from proteins under-
going neoplasia-specific tissue remodeling and generation of
cryptic epitopes. Based on the fact that Ig deposits in HPV16
skin are limited to dermal stroma (Figure 3B), we anticipate that
corresponding antigens derive from ECM proteins undergoing
remodeling in the surrounding stroma. Interestingly, the immu-
nological events occurring during premalignancy in HPV16
mice have striking similarities with various experimental and
human autoimmune disorders. For example, in patients with
epidermolysis bullosa acquisitia and bullous pemphigoid, de-
posits of self-specific antibodies are observed in the dermis
along basement membranes (Schaumburg-Lever et al., 1975;
Woodley et al., 1984). Similar to our observations in HPV16
mice, in experimental models of bullous pemphigoid and arthri-
tis, deposition of self-specific antibodies results in recruitment
of MCs and neutrophils prior to blister formation or arthritis
(Chen et al., 2002; Lee et al., 2002). Whether B cell responses
mediating chronic inflammation in premalignant HPV16 skin
are reactive toward self-antigens remains to be established.
The observation that circulating self-specific antibodies against
HPV16 E7 are detected in HPV16 mice suggests that premalig-
nant progression does involve autoantibody formation (Daniel
et al., 2003), the significance of which, with regard to chronic
inflammation, remains to be determined.
Involvement of T lymphocytes
To ensure that adoptively transferred B cells contained primed
and memory B cells capable of secreting Ig that homed to neo-
plastic skin, we isolated B lymphocytes from spleens and
lymph nodes of 3- to 6-month-old HPV16 mice (Figure 4). Pre-
vious studies demonstrated that memory B cells adoptively
transferred into RAG-1−/− mice maintained the ability to secrete
antibodies in the absence of T cell help (Hebeis et al., 2004).
When we evaluated HPV16/CD4−/−/CD8−/− mice, we found
characteristic Ig deposition and infiltration of innate immune
cells in premalignant skin (data not shown and Figure 1), sug-
gesting that B cell responses may be independent of mature
CD4+ and CD8+ T cells. A caveat to this is that while CD4−/−/
CD8−/− mice indeed lack CD4 and CD8α coreceptors, a small
residual population of T lymphocytes may be present and in-
volved in priming B lymphocytes (Locksley et al., 1993; Schil-
ham et al., 1993). Further studies are needed to address the
exact role of T cells in the induction of tumor-enhancing B
cell responses.
It has previously been reported that CD4+ T cells regulate
carcinoma latency in HPV16 mice via altering the presence of
CD11b+ and Gr-1+ immune cells in fully dysplastic skin (Daniel420et al., 2003). When we evaluated premalignant HPV16/CD4−/−
and HPV16/CD4−/−/CD8−/− tissues, we did not observe re-
duced percentages of CD45+, GR-1+, or mast cells as com-
pared to the dramatic reductions found in age-matched
HPV16/RAG-1−/− mice (Figure 1). Thus, our data indicate that
B cells are critical for establishing initial regulatory circuits lead-
ing to chronic innate immune cell infiltration during the earliest
stages of premalignant progression, and when absent, results
in significantly reduced premalignant progression and carci-
noma development. In contrast, CD4+ T lymphocytes do not
appear to regulate establishment of chronic inflammation, but
instead affect late-stage presence of innate immune cells and
modestly alter carcinoma latency (Daniel et al., 2003).
Adaptive immunity and cancer development: implications
A prevalent view of the relationship between adaptive immunity
and cancer is that adaptive immune cells exert a protective role
against developing neoplasms, i.e., immune surveillance (Dunn
et al., 2002), the existence of which remains a matter of debate
(Qin and Blankenstein, 2004). In this study, we report that ge-
netic elimination of mature B and T cells does not enhance
premalignant progression or carcinoma incidence, but rather
reduces it. These data are in contrast to epidemiological
studies of immunodeficient or immunosuppressed humans
who demonstrate increased risk of certain types of neoplasms,
including nonmelanoma skin cancer (Boshoff and Weiss, 2002).
This paradox is most logically explained by differences in can-
cer etiology between immunocompromised patients versus
HPV16/RAG-1−/− mice, where in the former, malignancies typi-
cally arise due to viral infection, e.g., HPV16-related cervical
and squamous carcinomas, Epstein-Barr virus-related non-
Hodgkin’s lymphoma, and Kaposi’s sarcoma associated with
human herpesvirus 8 (Boshoff and Weiss, 2002). The relatively
high incidence of these malignancies in immunocompromised
patients can at least partially be explained by their increased
susceptibility to viral infection and/or viral reactivation. In this
report, however, we analyzed the role of adaptive immunity
during premalignant progression in transgenic mice harboring
viral oncoproteins as opposed to virus-infected mice. Consis-
tent with our observations regarding absence of immune sur-
veillance during premalignant progression in HPV16 mice, in
human immunodeficiency virus-positive patients, incidence of
the most prevalent epithelial cancer types of nonviral etiology,
e.g., colon, prostate, breast, and ovarian, are similarly reduced
(Boshoff and Weiss, 2002).
Our data implicating B lymphocytes as enhancers of prema-
lignancy by potentiating chronic inflammation suggest that
passive transfer antibody therapies and active immunothera-
peutical approaches may have disparate outcomes when anti-
body responses are induced against solid malignancies as op-
posed to premalignant disease. The possibility of potentiating
malignant risk by activating humoral B cell responses is under-
scored by our data (Figure 7) and other studies reporting en-
hanced neoplastic progression and tumor growth following
passively transferred or actively produced antibodies (Barbera-
Guillem et al., 2000; Nyhus et al., 2001; Siegel et al., 2000).
These data suggest that enhanced neoplastic risk may follow
vaccination modalities in cancer-prone patients or patients
with premalignant disease via inadvertently inducing humoral
immune responses. That said, potential enhancement of
chronic tumor-promoting host responses could be circum-CANCER CELL : MAY 2005
A R T I C L Evented by the use of specifically engineered antibodies lacking
functional Fc domains that fail to interact with and/or stimulate
resident inflammatory cells.
In conclusion, data reported herein support a model in which
the adaptive immune system functionally interacts with the in-
nate immune system and that both components are critically
involved during the early stages of neoplastic progression. In
addition, this study suggests that pharmacological interven-
tions attenuating B cell activation or blocking B cell-mediated
recruitment of innate immune cells may be effective in prevent-
ing premalignant epithelial progression.
Experimental Procedures
Transgenic mice and histopathologic analyses
Generation and characterization of HPV16 mice and mice homozygous null
(−/−) for RAG-1 and CD4 and CD8a coreceptors have been described pre-
viously (Chen et al., 1994; Coussens et al., 1996; Mombaerts et al., 1992;
Rahemtulla et al., 1991). To generate HPV16 mice in the RAG-1−/−, CD4−/−,
and CD8−/− backgrounds, RAG-1+/−, CD4+/−, and CD8+/− mice were
backcrossed into the FVB/n strain to N15, N14, and N6, respectively, where
they were then intercrossed with HPV16 mice to generate breeding colonies
of HPV16/RAG-1−/−, HPV16/CD4−/−, HPV16/CD8−/−, and HPV16/CD4−/−/
CD8−/− mice. All mice were maintained within the UCSF Laboratory for Ani-
mal Care barrier facility according to IACUC procedures. Characterization
of neoplastic stages based on hematoxylin and eosin staining and keratin
intermediate filament expression for histologic examination have been re-
ported previously (Coussens et al., 1996; Daniel et al., 2003).
Flow cytometry
Single-cell suspensions were prepared from ears of negative littermate
[(−)LM] and transgenic mice as described previously (de Visser et al., 2004).
Cells were incubated for 10 min at 4°C with rat anti-mouse CD16/CD32
mAb (BD Biosciences, San Diego, CA) at a 1:100 dilution in PBS/BSA to
prevent nonspecific antibody binding. Subsequently, cells were washed and
incubated for 20 min with 50 l of 1:100 dilution of primary antibody fol-
lowed by two washes with PBS/BSA. 7-AAD (BD Biosciences) was added
(1:10) to discriminate between viable and dead cells. Data acquisition and
analysis were performed on a FACSCalibur using CellQuestPro software
(BD Biosciences). Data shown represent mean ± SEM. See the Supplemen-
tal Data section for specifics on primary antibody use.
Enzyme- and immunohistochemistry
Immunohistochemical (IHC) detection and chloroacetate esterase (CAE)
histochemistry was performed as previously described (Coussens et al.,
1996; Coussens et al., 1999; Coussens et al., 2000; de Visser et al., 2004).
All immunolocalization experiments were repeated on multiple tissue sec-
tions and included negative controls for determination of background stain-
ing, which was negligible. Data shown are representative of results obtained
following examination of tissues removed from a minimum of five different
mice per time point. Quantitative analysis of MCs and granulocytes was
performed by counting cells in five high-power fields (40×) per age-matched
tissue section from five mice per group. Data presented reflect the mean
total cell count per field from the ventral ear leaflet.
Fluorescent angiography
Anesthetized mice were injected i.v. with 0.05 mg FITC-labeled tomato lec-
tin (Lycopersicon esculentum; Vector) and analyzed using a laser-scanning
confocal Zeiss LSM510 META microscope with a Zeiss LSM Image Exam-
iner as previously described (van Kempen et al., 2002).
Gelatinase solution assay
Protein lysates were prepared for enzyme solution assays as previously
described (Rhee et al., 2004). Fluorescence was measured (excitation 485
nm, emission 530 nm) on a SpectraMax Gemini spectrophotometer (Molec-
ular Devices, Sunnyvale, CA) operated by SoftMax Pro 4.3 software (Molec-
ular Devices). Metalloproteinase inhibition was performed in the presence
of 4.0 mM 1,10-phenanthroline (Sigma, St. Louis, MO). Change in relativeCANCER CELL : MAY 2005fluoresence units (RFU)/min/g tissue protein was determined using Soft-
Max Pro 4.3 software (Molecular Devices).
Substrate zymography
Fresh-frozen ears from (−)LM or transgenic mice were weighed, and protein
lysates were prepared for gelatin substrate zymography as previously de-
scribed (Coussens et al., 2000; Rhee et al., 2004).
ELISA
VEGF-A ELISA
Tissue lysates were prepared as described above for substrate zymogra-
phy. VEGF-A levels in tissue lysates were assayed using the quantikine
mouse VEGF-A immunoassay kit (R&D systems, Minneapolis, MN) as de-
scribed by the manufacturer, using 50 g of protein. Optical density was
measured at 450 nm with wavelength correction set to 540 nm on a
SpectraMax 340 spectrophotomoter (Molecular Devices). Antibody concen-
trations were calculated using SoftMax Pro 4.1 (Molecular Devices).
Immunoglobulin ELISA
Serum ELISA to analyze Ig levels was performed as described by the manu-
facturer’s recommendations using the clonotyping system-HRP kit (South-
ernBiotech, Birmingham AL). Optical density was measured at 405 nm on
a SpectraMax 340 spectrophotomoter (Molecular Devices, Sunnyvale, CA).
Samples were assayed from at least four mice per category. Ig concentra-
tions were calculated using SoftMax Pro 4.1 (Molecular Devices).
Immunofluorescence detection of immunoglobulin deposition
Immunofluorescent detection of immunoglobulin subtypes was performed
essentially as described (de Visser et al., 2004). Data shown are representa-
tive of results obtained following examination of tissues removed from a
minimum of four mice per category. All IF experiments included negative
controls for determination of background staining that was negligible. Spe-
cific details on antibodies used are provided in Supplemental Data.
Adoptive transfer of B lymphocytes
Spleen and lymph nodes from HPV16 mice (3–6 months of age) were ho-
mogenized through a 70 m nylon filter (Falcon). Single-cell suspensions
were treated with 1xPharM Lyse ammonium chloride lysing reagent (BD
Biosciences) for 5 min to remove erythrocytes. Cells were washed with
DMEM containing 5% FBS and were enriched for viable lymphocytes over a
Lympholyte-M gradient (Cedarlane Laboratories, Hornby, Ontario, Canada).
Cells were washed with DMEM 5% FBS, followed by a wash with PBS
containing 1% FBS. To exclude a potential activating effect of labeling B
cells with antibodies, a negative purification procedure was applied by re-
moving all non-B lymphocytes using the Mouse B Cell Recovery Column
Kit (Cedarlane). Briefly, 1 × 108 cells were incubated with antibody cocktail
for 1 hr on ice. Antibody-labeled cells were removed by affinity chromatog-
raphy using immunocolumns containing agarose beads. Eluted cells were
washed with PBS, and purity of the B cell population confirmed by flow
cytometry using APC-anti-CD19, FITC-anti-B220, PE-anti-CD8, FITC-anti-
CD4, FITC-anti-γδ TCR, and FITC-anti-NK1.1 (1:100; eBioscience). Percent-
ages of CD4+ and CD8+ T cells were <0.1%, γδ TCR+ cells were <2%, and
NK1.1+ cells <0.4% of the total. In addition, we confirmed that the enrich-
ment process did not result in activation of B cells and/or select for a subset
of activated B lymphocytes by comparing activation phenotypes before and
after the enrichment procedure by flow cytometry using PE-anti-CD44, PE-
anti-CD23, PE-anti-MHC-II, PE-anti-CD69, and PE-anti-CD138 (1:100; BD
Biosciences). 7 × 106 B cells were adoptively transferred into 1-month-old
HPV16/RAG-1−/− mice in 200 l PBS by tail vein injection. For in vivo deple-
tion of potentially contaminating CD4+ T cells after adoptive transfer, mice
were injected twice (on the day of transfer and 1 day after transfer) with 200
g each of purified GK1.5 antibody.
Serum transfer
Serum pools were prepared from HPV16 or wild-type FVB/n mice at 3–6
months of age. Serum was transferred into HPV16/RAG-1−/− mice by i.p.
injection of 200 l serum at weekly intervals. Serum transfer into HPV16/
RAG-1−/− mice was started at 1 month of age and continued for 4 months.
Statistical analyses
Statistical analyses were performed using GraphPad Prism version 4 and/
or InStat version 3.0a for Macintosh (GraphPad Software, San Diego, CA).421
A R T I C L ESpecific tests used were Mann-Whitney (unpaired, nonparametric, two-
tailed), unpaired t test Welch corrected, Fishers exact test, and Log rank
analysis. p values < 0.05 were considered statistically significant.
Supplemental Data
The Supplemental Data for this article, including Supplemental Experimen-
tal Procedures and Figures, can be found at http://www.cancercell.org/cgi/
content/full/7/5/411/DC1/.
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